ABBOTT REPORTS FIRST-QUARTER 2020 RESULTS

2016 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after­tax charges of $559 million, or $0.37 per share,

2016 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $2.012 billion, or $1.35 per share, for intangible amortization expense,

2016 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $772 million, or $0.52 per share, for intangible amortization expense,

2015 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $415 million, or $0.27 per share, for intangible amortization

FIRST-QUARTER DOUBLE-DIGIT OPERATIONAL SALES GROWTH FIRST-QUARTER ADJUSTED EPS FROM CONTINUING OPERATIONS OF $0.47, ABOVE PREVIOUS GUIDANCE RANGE AND REFLECTING 38 PERCENT GROWTH;

5 2014 Net Earnings from Discontinued Operations, excluding Specified Items, excludes net after-tax charges of $65 million, or $0.05 per share, primarily related to

4 2011 Net Earnings Excluding Specified Items excludes after-tax charges of $142 million, or $0.09 per share, associated with the acquisition of Solvay Pharmaceuticals, $107 million,

Press Release Abbott Reports 17.4 Percent Sales Growth and 12.3 Percent Ongoing Earnings-Per-Share Growth in First Quarter Worldwide Durable Growth Business Sales Increased 24.3